Essex Bio-Technology Reports Strong Profit Growth Despite Turnover Decline

An update from Essex Bio-Technology ( (HK:1061) ) is now available.

Essex Bio-Technology Limited reported its audited consolidated financial results for the year ended December 31, 2024. The company experienced a slight decrease in turnover by 3.9% in HKD terms but achieved an 11.6% increase in profit for the year. The financial position improved with a 5.5% increase in total assets and a 10.4% rise in net assets. The company also declared a 33.3% increase in dividends per ordinary share. These results indicate a strong financial performance despite a slight decline in turnover, reflecting effective cost management and operational efficiency.

More about Essex Bio-Technology

Essex Bio-Technology Limited is a company incorporated in the Cayman Islands, operating within the biotechnology industry. The company focuses on developing and marketing biopharmaceutical products, with a primary emphasis on ophthalmology and dermatology treatments.

YTD Price Performance: -3.74%

Average Trading Volume: 301,553

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.63B

Find detailed analytics on 1061 stock on TipRanks’ Stock Analysis page.